Exemestane
Exemestane structure
|
Common Name | Exemestane | ||
|---|---|---|---|---|
| CAS Number | 107868-30-4 | Molecular Weight | 296.403 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 453.7±45.0 °C at 760 mmHg | |
| Molecular Formula | C20H24O2 | Melting Point | 155.13°C | |
| MSDS | Chinese USA | Flash Point | 169.0±25.7 °C | |
| Symbol |
GHS07, GHS08 |
Signal Word | Danger | |
|
High throughput quantification of prohibited substances in plasma using thin film solid phase microextraction.
J. Chromatogr. A. 1374 , 40-9, (2014) Simple, fast and efficient sample preparation approaches that allow high-throughput isolation of various compounds from complex matrices are highly desired in bioanalysis. Particularly sought are methods that can, without sacrificing time, easily remove matri... |
|
|
Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells.
Mol. Med. Report. 12 , 456-62, (2015) Breast cancer is associated with high levels of incidence, morbidity and mortality; therefore, the identification of effective chemopreventive strategies is crucial. It is important for clinicians to be able to identify the populations at risk who would benef... |
|
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N. Engl. J. Med. 371(2) , 107-18, (2014) Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive ear... |
|
|
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
J. Clin. Oncol. 31(11) , 1391-7, (2013) A 56-year-old postmenopausal woman with a recent diagnosis of breast cancer was referred to discuss adjuvant therapy. Annual screening mammogram demonstrated a suspicious mass in the left breast. Ultrasound-guided core needle biopsy revealed an infiltrating d... |
|
|
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Cancer 120(23) , 3744-51, (2014) Although fatigue, sleep disturbance, depression, and anxiety are associated with pain in breast cancer patients, it is unknown whether acupuncture can decrease these comorbid symptoms in cancer patients with pain. The objective of this study was to evaluate t... |
|
|
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Ned. Tijdschr. Geneeskd. 150(52) , 2863-9, (2006) Postmenopausal patients with hormone-sensitive breast cancer may be eligible for adjuvant hormone therapy. - For years, tamoxifen was the treatment of choice. - However, the side effects associated with tamoxifen, such as endometrial cancer and thromboembolic... |
|
|
Sensitivity of endometrial cancer cells from primary human tumor samples to new potential anticancer peptide lactaptin.
J. Cancer Res. Ther. 11 , 345-51, (2015) Endometrial carcinoma is the most common gynecologic malignancy which is associated with a poor prognosis when diagnosed at an advanced stage; therefore, the discovery of efficacious new drugs is required to reinforce conventional chemotherapy. Short-term cul... |
|
|
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
J. Clin. Oncol. 31(11) , 1398-404, (2013) In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non-cross-resistant with nonsteroid... |
|
|
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
N. Engl. J. Med. 372(2) , 162-70, (2015) In a 66-year-old woman, enlarged lymph nodes were seen on routine breast imaging. She had received a diagnosis of ductal carcinoma 6 years earlier and had been treated with radiation and chemotherapy, followed by anastrozole. A diagnostic procedure was perfor... |
|
|
No pain, no gain: a fallacy so far.
J. Clin. Oncol. 33(3) , 235-7, (2015)
|